Public Health - Clinical Practice - Prova Education

Episodes 1-16 of 34

- Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP
  Peer
- Peter Pickkers, MD, PhD
  Peer
- Alexander Zarbock, MD
  Peer
8
CME/CE
Cases in Acute Kidney Injury: Applications for Clinical Practice
Cases in Acute Kidney Injury: Applications for Clinical Practice
0.25 credits
Cases in Acute Kidney Injury: Applications for Clinical Practice
0.25 credits
- Mark Dunbar, OD, FAAO
  Peer
- Diana V. Do, MD
  Peer
4
CME/CE
A National Eye Institute Initiative—Ensuring the Health of Patients and Staff in Eye Health Practices During COVID-19
A National Eye Institute Initiative—Ensuring the Health of Patients and Staff in Eye Health Practices During COVID-19
0.25 credits
A National Eye Institute Initiative—Ensuring the Health of Patients and Staff...
0.25 credits
- Diana Shechtman, OD, FAAO
  Peer
- Charles Wykoff, MD, PhD
  Peer
3
CME/CE
A National Eye Institute Initiative—Practice Strategies to Optimize Continuity of Care for Eye Health During COVID-19
A National Eye Institute Initiative—Practice Strategies to Optimize Continuity of Care for Eye Health During COVID-19
0.25 credits
A National Eye Institute Initiative—Practice Strategies to Optimize Continuit...
0.25 credits
- Jennifer Caudle, DO
  Peer
- Nicole Bernard Washington, DO, MPH
  Peer
31
CME/CE
Taking Care of Yourself While Taking Care of Others During COVID-19
Taking Care of Yourself While Taking Care of Others During COVID-19
0.25 credits
Taking Care of Yourself While Taking Care of Others During COVID-19
0.25 credits
- Jennifer Caudle, DO
  Peer
- Brian P. McDonough, MD, FAAFP
  Peer
18
CME/CE
How Primary Care Clinicians on the Frontline Are Managing Patients During the COVID-19 Pandemic
How Primary Care Clinicians on the Frontline Are Managing Patients During the COVID-19 Pandemic
0.25 credits
How Primary Care Clinicians on the Frontline Are Managing Patients During the...
0.25 credits
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
- C. Michael Gibson, MD, MS
  Peer
31
CME/CE
COVID-19 & Cardiovascular Considerations
COVID-19 & Cardiovascular Considerations
0.25 credits
COVID-19 & Cardiovascular Considerations
0.25 credits
- Jay L. Koyner, MD
  Peer
- Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP
  Peer
- John A. Kellum, MD, MCCM
  Peer
12
CME/CE
Early Recognition of Acute Kidney Injury: What’s the Role of Biomarkers?
Early Recognition of Acute Kidney Injury: What’s the Role of Biomarkers?
0.25 credits
Early Recognition of Acute Kidney Injury: What’s the Role of Biomarkers?
0.25 credits
- Ravindra L. Mehta, MD
  Peer
- Rajit K. Basu, MD, MS, FCCM
  Peer
15
CME/CE
Acute Kidney Injury: Finding a Pathway to Improved Patient Outcomes
Acute Kidney Injury: Finding a Pathway to Improved Patient Outcomes
0.25 credits
Acute Kidney Injury: Finding a Pathway to Improved Patient Outcomes
0.25 credits
3
FDA Drug Information Updates
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (L...
- Kathy King, RDN
  Peer
- Kristin Kirkpatrick, MS, RDN
  Peer
6
NutritionEdge
Skinny Liver: A Closer Examination of Fatty Liver Disease
Skinny Liver: A Closer Examination of Fatty Liver Disease
Skinny Liver: A Closer Examination of Fatty Liver Disease
2
FDA Drug Information Updates
FDA’s Role in Foreign Drug Manufacturing
FDA’s Role in Foreign Drug Manufacturing
FDA’s Role in Foreign Drug Manufacturing
3
FDA Drug Information Updates
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
1
FDA Drug Information Updates
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
2
FDA Drug Information Updates
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Ser...
- Matt Rosenberg, MD
  Peer
- Aiden Harrington, ANP, CNM
  Peer
13
Clinician's Roundtable
STI Screening & Counseling Strategies for Transgender Patients
STI Screening & Counseling Strategies for Transgender Patients
STI Screening & Counseling Strategies for Transgender Patients
2
FDA Drug Information Updates
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard

Prev
1
2
3
Next

1/3